ArticleIranian biomedical journal2026
Rescue a Reassortant Human-Bovine Rotavirus and a Recombinant NSP3-EGFP Rotavirus Serotype G1.
Article in Iranian biomedical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Human group A rotaviruses (RVs), with an 11-segmented double-stranded RNA genome, are a cause of viral gastroenteritis in infants and young children. Despite the availability of effective live-attenuated vaccines, RV infection is still a global health challenge. Hence, a reverse genetics system enabling the manipulation of RV segments, such as genome reassortment, is essential for developing new RV vaccines. Herein, a reverse genetics system was used to rescue a reassortant human-bovine RV, incorporating the VP7 gene segment from the human RV strain Wa (serotype G1) and a recombinant RV. Methods: To rescue a reassortant human-bovine RV, we used a reverse genetics system in which 13 plasmid constructs were co-transfected into BHK-T7 cells. In this method, 10 plasmids were derived from bovine RV, one encoded the human RV VP7 segment of serotype G1, and two expressed the capping enzyme subunits of vaccinia virus. We also created a recombinant RV featuring enhanced green fluorescent protein (EGFP) by replacing the bovine NSP3 plasmid with an NSP3-EGFP construct, where EGFP expression was regulated by an internal ribosomal entry site. Results: Our results showed successful rescue of the reassortant human-bovine RV and the recombinant strain, with the NSP3-EGFP construct facilitating EGFP translation across multiple RV passages. Replacing the NSP3 gene segment of bovine RV with the release of a recombinant RV enabled EGFP expression in several RV passages. Conclusion: Our study establishes the feasibility of using a reverse genetics system to generate a live-attenuated RV vaccine candidate, potentially enhancing future control efforts against RV infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.